Key clinical point: Real‐world data revealed that patients with hemophilia A with inhibitors had lower health‐related quality of life while receiving standard treatment.
Major finding: Mean scores in health-related quality of life domains related to impairments were reported to occur “sometimes” to “often” in patients receiving treatment.
Study details: An international, noninterventional study of 103 patients with hemophilia A.
Disclosures: The study was funded by F. Hoffmann-La Roche. The authors reported financial disclosures related to Baxalta, Bayer, CSL Behring, Kaketsuken, Novo Nordisk, Pfizer, and several others.
Mahlangu J et al. Haemophilia. 2019 Apr 24. doi: 10.1111/hae.13731.